Our Targeted Peptide Technology (TPT) eliminates a subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. Autoimmune diseases occur when the immune system attacks the body’s own cells, mistaking them for pathogens. Certain molecular patterns, antigens, are displayed on all cell surfaces; these allow the immune system to distinguish self from non-self cells and healthy from infected cells. When a cell displays a non-self molecular pattern, that alerts the immune system to the presence of a pathogen and helps identify the pathogen. This recognition initiates an immune response: acute inflammation followed by targeted destruction of invaders and of compromised self-cells.
Our patented peptides were designed to function in all MHC-II phenotypes. We expect our TPT compounds to enable the body to destroy the cells that help trigger autoimmune diseases.When certain cells in the body ingest foreign, damaged or infected cells, they display a receptor on the cell’s surface, the MHC-II receptor (Major Histocompatibility Complex II). MHC-II allows other immune cells, such as T-cells, to identify the unwanted cell and cause the cell’s death, eliminating the threat. Our research indicates that the self-peptide CLIP (Class II-associated invariant chain peptide) can be displayed on external MHC-II receptors, preventing T-cells from recognizing an antigen-less MHC-II receptor and from causing the death of antigen-presenting cells. This disruption may prolong a non-specific immune activation. Thus, we believe that CLIP prolongs the activity of pro-inflammatory cells and leads to chronic inflammation. Current therapies that combat these immune disorders generally focus on eliminating pro-inflammatory cells and/or their pro-inflammatory signals. Such therapies work broadly and may be non-specific, which can weaken or suppress the immune system and hamper a patient’s ability to fight secondary infections. VG Life Sciences has used computational models to produce a synthetic peptide that is selective and possesses binding abilities superior to CLIP. This allows our peptide to knock out CLIP’s signaling ability, eliminating the destructive inflammatory process. As our peptide is narrow in its target, it may avoid drawbacks characteristic of current therapies. Our patented peptides were designed to function in all MHC-II phenotypes. We expect our TPT compounds to enable the body to destroy the cells that help trigger autoimmune diseases. We also believe that various conditions may respond to TPT treatment, including traumatic brain injury, hypertension, preeclampsia, glioblastoma, Type I and Type II diabetes, Lyme disease, Crohn’s disease, ulcerative colitis, multiple sclerosis, and transplant rejection.